Marker Therapeutics Net Income

Marker Therapeutics (MRKR) currently reports a net income of $-12T as of June 2026. That compares with $-15M in the prior-year period — down 83269201.7% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Marker Therapeutics's net income history and peer comparisons.

Marker Therapeutics's net income decreased from $-15M to $-12T — a 83269201.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Marker Therapeutics's net income of $-12T is lower than the Healthcare sector average of $16B. That is roughly 73878.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Marker Therapeutics reported $-12T in net income as of June 2026. That compares with $-15M in the prior-year period — down 83269201.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-12T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Marker Therapeutics, and consider following MRKR for alerts when major investors trade the stock.